Aurobindo Pharma – Q1FY27 Earnings Snapshot
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ | CNBC-TV18 Poll | Miss/Beat |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 9,150.3 | 8,853 | 7,868 | ▲ 16% | ▲ 3.4% | 9,030 | ✅ Beat |
| EBITDA (₹ Cr) | 1,881 | 1,750 | 1,603 | ▲ 17% | ▲ 7.5% | 1,848 | ✅ Beat |
| EBITDA Margin | 20.6% | 19.8% | 20.4% | ▲ 20 bps | ▲ 80 bps | 20.5% | ✅ Beat |
| Net Profit (₹ Cr) | 1,032 | 921 | 824 | ▲ 28% | ▲ 12.1% | 982 | ✅ Beat |
| EPS (₹) | 17.78 | 15.86 | 14.20 | ▲ 25% | ▲ 12.1% | — | — |
Verdict
Aurobindo Pharma delivered a strong Q1FY27 performance, reporting double-digit growth in revenue, EBITDA, and net profit along with healthy margin expansion. The company beat CNBC-TV18 estimates across all key financial metrics, highlighting robust operational execution and sustained profitability.
Cummins India Q1 FY27 Results – Revenue Beats, Margins Under Pressure
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ | CNBC-TV18 Est. | Miss/Beat |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,426 | 3,011 | 2,907 | ▲ 18% | ▲ 14% | ₹3,286 Cr | Beat |
| EBITDA (₹ Cr) | 616 | 642 | 624 | ▼ 1% | ▼ 4% | ₹689 Cr | Miss |
| EBITDA Margin | 18.0% | 21.3% | 21.5% | ▼ 350 bps | ▼ 330 bps | 21% | Miss |
| Net Profit (₹ Cr) | 609 | 649 | 604 | ▲ 1% | ▼ 6% | ₹652 Cr | Miss |
| EPS (₹) | 21.98 | 23.43 | 21.79 | ▲ 1% | ▼ 6% | — | — |
Datamatics Global Q1 FY27 Results
CMP: ₹877 | M.Cap: ₹5,192 Cr | P/E: 20.5
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 514 | 519 | 468 | ▲ 10% | ▼ 1.0% |
| EBITDA (₹ Cr) | 101 | 111 | 75.9 | ▲ 33% | ▼ 9.0% |
| Net Profit (₹ Cr) | 72.4 | 44.9 | 50.4 | ▲ 44% | ▲ 61.2% |
| EPS (₹) | 12.24 | 7.48 | 8.52 | ▲ 44% | ▲ 63.6% |
Verdict
Datamatics Global delivered a strong operational performance in Q1 FY27, with net profit and EPS rising 44% YoY despite nearly flat sequential revenue. EBITDA grew 33% YoY, reflecting continued margin expansion and improved operational efficiency. While revenue and EBITDA moderated slightly on a QoQ basis, the sharp improvement in profitability indicates healthy execution and cost management, making the overall quarter fundamentally strong.
Kirloskar Industries – Q1 FY27 Results Review
CMP: ₹3,804 | M.Cap: ₹3,991 Cr | P/E: 13.0
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 1,772 | 1,817 | 1,698 | ▲ 4% | ▼ 2.5% |
| EBITDA (₹ Cr) | 216 | 225 | 217 | ▼ 1% | ▼ 4.0% |
| Net Profit (₹ Cr) | 82.3 | 126 | 238 | ▼ 55% | ▼ 34.7% |
| EPS (₹) | 78.35 | 119.59 | 228.45 | ▼ 66% | ▼ 34.5% |
Verdict
Kirloskar Industries reported modest revenue growth during Q1 FY27, with sales increasing 4% YoY despite a slight sequential decline. However, operating performance weakened as EBITDA remained largely flat YoY and declined on a QoQ basis. Profitability came under significant pressure, with net profit falling 55% YoY and 34.7% QoQ, while EPS declined 66% YoY and 34.5% QoQ. Overall, the quarter reflects stable topline performance but considerably weaker earnings, indicating pressure on margins and overall profitability.
Mindspace Business Parks REIT – Q1 FY27 Results
CMP: ₹493 | M.Cap: ₹32,592 Cr | P/E: 41.8
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 946 | 890 | 740 | ▲ 28% | ▲ 6.3% |
| EBITDA (₹ Cr) | 714 | 683 | 550 | ▲ 30% | ▲ 4.5% |
| Net Profit (₹ Cr) | 272 | 209 | 167 | ▲ 67% | ▲ 30.1% |
| EPS (₹) | 3.96 | 3.06 | 2.57 | ▲ 54% | ▲ 29.4% |
Verdict
Mindspace Business Parks REIT delivered a strong quarter with healthy revenue growth and robust profitability. Sales increased 28% YoY, while EBITDA grew 30%, reflecting steady operational performance. Net Profit surged 67% YoY and EPS rose 54%, significantly outpacing revenue growth, indicating improving operating efficiency and strong earnings momentum. Overall, the results highlight sustained business growth backed by higher profitability.
Bikaji Foods Q1 FY27 Results
CMP: ₹650 | M.Cap: ₹16,310 Cr | P/E: 62.4
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 734 | 721 | 653 | ▲ 12% | ▲ 1.8% |
| EBITDA (₹ Cr) | 99.0 | 87.7 | 96.3 | ▲ 3% | ▲ 12.9% |
| Net Profit (₹ Cr) | 59.5 | 56.0 | 58.5 | ▲ 0% | ▲ 6.3% |
| EPS (₹) | 2.40 | 2.25 | 2.39 | ▲ 0% | ▲ 6.7% |
Verdict
Revenue growth remained healthy with a strong 12% YoY increase, indicating steady demand across the company’s product portfolio. However, EBITDA and net profit registered only marginal year-on-year growth, suggesting pressure on operating margins. On a sequential basis, both profitability and earnings improved, reflecting stable operational execution and better cost management during the quarter.
Bodal Chemicals – Q1 FY27 Results Snapshot
CMP: ₹75.2 | M.Cap: ₹950 Cr | P/E: 13.8
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 709 | 588 | 454 | ▲ 56% | ▲ 20.6% |
| EBITDA (₹ Cr) | 68.9 | 68.6 | 47.6 | ▲ 45% | ▲ 0.4% |
| Net Profit (₹ Cr) | 30.4 | 32.1 | 9.53 | ▲ 219% | ▼ 5.3% |
| EPS (₹) | 2.41 | 2.55 | 0.76 | ▲ 217% | ▼ 5.5% |
Verdict
Bodal Chemicals reported a strong Q1 FY27 performance with revenue rising 56% YoY to ₹709 crore, driven by healthy business momentum. EBITDA increased 45% YoY while remaining stable sequentially, reflecting resilient operating performance. Net profit surged 219% YoY and EPS more than tripled compared to the year-ago period, although both witnessed a marginal QoQ decline. Overall, the quarter reflects robust earnings growth, improving profitability, and healthy operational execution, keeping the overall outlook positive.
GNFC Q1 FY27 Results
CMP: ₹538 | M.Cap: ₹7,905 Cr | P/E: 7.6
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 2,238 | 2,208 | 1,601 | ▲ 40% | ▲ 1.4% |
| EBITDA (₹ Cr) | 393 | 482 | 31 | ▲ 1,168% | ▼ 18.5% |
| Net Profit (₹ Cr) | 312 | 396 | 83 | ▲ 276% | ▼ 21.2% |
| EPS (₹) | 21.23 | 26.95 | 5.65 | ▲ 276% | ▼ 21.2% |
Verdict
GNFC delivered an excellent year-on-year performance in Q1 FY27, supported by a sharp recovery in profitability. Sales grew 40% YoY, while EBITDA surged 1,168% and net profit increased 276%, reflecting significantly improved operating performance. On a sequential basis, revenue remained largely stable, but EBITDA and net profit declined due to margin normalization after a strong previous quarter. Overall, the results indicate robust operational recovery with healthy revenue growth, though quarterly profitability moderated from the exceptionally strong March quarter.
Subex – Q1 FY27 Results
CMP: ₹13.8 | M.Cap: ₹779 Cr | P/E: 24.1
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 79.4 | 73.0 | 66.4 | ▲ 20% | ▲ 8.8% |
| EBITDA (₹ Cr) | 15.0 | 9.16 | 3.93 | ▲ 282% | ▲ 63.8% |
| Net Profit (₹ Cr) | 14.2 | 9.93 | 12.8 | ▲ 11% | ▲ 43.0% |
| EPS (₹) | 0.25 | 0.18 | 0.23 | ▲ 9% | ▲ 38.9% |
Verdict
Subex reported a strong Q1 FY27 performance with revenue rising ▲20% YoY and ▲8.8% QoQ. EBITDA surged ▲282% YoY, reflecting a significant improvement in operating efficiency and margins. Net profit increased ▲11% YoY and ▲43% QoQ, while EPS also posted healthy growth. Overall, the quarter indicates improving profitability, stronger execution, and positive earnings momentum.
Mayur Uniquoters – Q1 FY27 Results
CMP: ₹769 | M.Cap: ₹3,338 Cr | P/E: 16.1
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 269 | 273 | 216 | ▲ 25% | ▼ 1.5% |
| EBITDA (₹ Cr) | 58.9 | 85.7 | 43.0 | ▲ 37% | ▼ 31.3% |
| Net Profit (₹ Cr) | 56.1 | 59.4 | 40.7 | ▲ 38% | ▼ 5.6% |
| EPS (₹) | 12.92 | 13.68 | 9.37 | ▲ 38% | ▼ 5.6% |
Verdict
Mayur Uniquoters delivered a strong year-on-year performance in Q1 FY27, with revenue rising 25%, EBITDA increasing 37%, and net profit and EPS growing 38%, reflecting healthy demand and improved profitability. On a sequential basis, however, revenue declined 1.5%, while EBITDA and net profit fell 31.3% and 5.6%, respectively, indicating moderation after a strong preceding quarter. Despite the QoQ softness, the company’s robust YoY growth and healthy earnings profile suggest that the overall quarterly performance remains positive from a long-term perspective.
eClerx Services – Q1 FY27 Results Snapshot
CMP: ₹1,918 | M.Cap: ₹18,035 Cr | P/E: 24.7
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 1,152 | 1,107 | 935 | ▲ 23% | ▲ 4.1% |
| EBITDA (₹ Cr) | 265 | 283 | 224 | ▲ 18% | ▼ 6.4% |
| Net Profit (₹ Cr) | 164 | 190 | 142 | ▲ 16% | ▼ 13.7% |
| EPS (₹) | 17.47 | 20.13 | 14.87 | ▲ 17% | ▼ 13.2% |
Verdict
Revenue growth remained strong with a healthy 23% YoY increase, reflecting robust business momentum. However, sequential profitability softened as EBITDA, net profit, and EPS declined on a QoQ basis, indicating margin pressure despite continued topline growth.
Sandesh Ltd. Q1 FY27 Results
CMP: ₹990 | M.Cap: ₹760 Cr | P/E: 7.0
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 458 | 211 | 73.3 | ▲ 525% | ▲ 117% |
| EBITDA (₹ Cr) | 19.4 | -34.9 | 18.1 | ▲ 7% | ▲ Turned Positive |
| Net Profit (₹ Cr) | 99.5 | -34.5 | 58.0 | ▲ 72% | ▲ Turned Positive |
| EPS (₹) | 131.44 | -45.63 | 76.68 | ▲ 71% | ▲ Turned Positive |
Verdict
Sandesh Ltd. delivered an exceptional Q1 FY27 performance, with revenue surging 525% YoY and 117% QoQ. The company returned to profitability on a sequential basis as EBITDA and net profit turned positive, while net profit and EPS also posted strong year-on-year growth. Overall, the quarter reflects a sharp operational recovery supported by robust revenue expansion and significantly improved earnings.
T.V. Today Network Q1 FY27 Results
CMP: ₹117 | Market Cap: ₹694 Cr | P/E: 25.4
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 206 | 213 | 198 | ▲ 4% | ▼ 3.3% |
| EBITDA (₹ Cr) | 15.8 | 4.56 | 4.21 | ▲ 275% | ▲ 246% |
| Net Profit (₹ Cr) | 10.3 | 9.02 | 7.35 | ▲ 38% | ▲ 14.2% |
| EPS (₹) | 1.72 | 1.51 | 1.23 | ▲ 40% | ▲ 13.9% |
Verdict
Revenue growth remained modest with sales rising 4% YoY, while declining 3.3% sequentially. However, the company delivered a significant improvement in profitability, with EBITDA surging 275% YoY and 246% QoQ, reflecting strong margin expansion and improved cost efficiencies. Net profit increased 38% YoY to ₹10.3 crore, supported by healthy operational performance, while EPS grew 40% YoY. Overall, the quarter highlights a meaningful turnaround in operating performance despite muted revenue growth.
Aster DM Quality – Q1 FY27 Results Snapshot
CMP: ₹842 | M.Cap: ₹73,412 Cr | P/E: 203.4
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 1,311 | 1,182 | 1,078 | ▲ 22% | ▲ 10.9% |
| EBITDA (₹ Cr) | 256 | 224 | 202 | ▲ 27% | ▲ 14.3% |
| Net Profit (₹ Cr) | 29.3 | 154 | 93.6 | ▼ 69% | ▼ 81.0% |
| EPS (₹) | 0.31 | 2.71 | 1.65 | ▼ 81% | ▼ 88.6% |
Verdict
Revenue and EBITDA posted healthy double-digit growth on both a YoY and QoQ basis, reflecting strong operational momentum during the quarter. However, net profit and EPS declined sharply despite the robust topline performance, suggesting the impact of exceptional items, higher depreciation, finance costs, or other non-operating expenses. Overall, the operating business remains strong, but the steep decline in profitability is the key monitorable for investors.
Cohance Life Sciences – Q1 FY27 Results
CMP: ₹429 | M.Cap: ₹16,418 Cr | P/E: 152.5
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 422 | 619 | 549 | ▼ 23% | ▼ 31.8% |
| EBITDA (₹ Cr) | 1.16 | 98.7 | 112 | ▼ 99% | ▼ 98.8% |
| Net Profit (₹ Cr) | -45.2 | 8.31 | 46.4 | ▼ 144% | ▼ 644% |
| EPS (₹) | -0.63 | 0.51 | 1.28 | ▼ 149% | ▼ 224% |
Verdict
Weak quarter with sharp declines across revenue, EBITDA, and profitability. The company slipped into a net loss, reflecting significant operational pressure. The steep contraction in operating earnings indicates margin stress, while the negative EPS highlights the impact on shareholder returns. Investors may watch upcoming quarters for signs of demand recovery, margin improvement, and a return to profitability.
PB Fintech – Q1 FY27 Results Snapshot
CMP: ₹1,620 | M.Cap: ₹74,398 Cr | P/E: 99.4
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 1,888 | 2,061 | 1,348 | ▲ 40% | ▼ 8.4% |
| EBITDA (₹ Cr) | 137 | 212 | 34.4 | ▲ 298% | ▼ 35.4% |
| Net Profit (₹ Cr) | 163 | 261 | 84.7 | ▲ 93% | ▼ 37.5% |
| EPS (₹) | 3.52 | 5.64 | 1.84 | ▲ 91% | ▼ 37.6% |
Verdict
PB Fintech delivered a strong year-on-year performance in Q1 FY27, with revenue rising ▲ 40%, EBITDA surging ▲ 298%, and net profit growing ▲ 93%, highlighting continued strength in its core business and improving profitability. However, on a sequential basis, revenue, EBITDA, net profit, and EPS moderated compared to the previous quarter, indicating a softer quarter after a strong Q4. Despite the QoQ slowdown, the company’s overall earnings trajectory remains healthy, supported by robust operating performance and sustained business expansion.
Biocon – Q1 FY27 Results Snapshot
CMP: ₹425 | M.Cap: ₹68,781 Cr | P/E: 94.6
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 4,336 | 4,517 | 3,942 | ▲ 10% | ▼ 4.0% |
| EBITDA (₹ Cr) | 847 | 1,020 | 766 | ▲ 11% | ▼ 17.0% |
| Net Profit (₹ Cr) | 137 | 199 | 89.2 | ▲ 54% | ▼ 31.2% |
| EPS (₹) | 0.87 | 0.78 | 0.23 | ▲ 278% | ▲ 11.5% |
Verdict
Biocon delivered a healthy operational performance with double-digit YoY growth in revenue and EBITDA, while net profit and EPS recorded strong gains over the corresponding quarter last year. However, the company witnessed sequential declines in sales, EBITDA, and net profit compared to the March quarter, indicating a softer quarter on a QoQ basis despite maintaining positive annual growth momentum.
Navin Fluorine International – Q1 FY27 Results
CMP: ₹7,610 | M.Cap: ₹38,977 Cr | P/E: 49.0
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 1,045 | 938 | 725 | ▲ 44% | ▲ 11.4% |
| EBITDA (₹ Cr) | 357 | 321 | 207 | ▲ 73% | ▲ 11.2% |
| Net Profit (₹ Cr) | 243 | 213 | 117 | ▲ 108% | ▲ 14.1% |
| EPS (₹) | 47.43 | 41.48 | 23.62 | ▲ 101% | ▲ 14.3% |
Verdict
Navin Fluorine International delivered a strong Q1 FY27 performance, reporting robust double-digit sequential growth across revenue, EBITDA, net profit, and EPS. The company also posted exceptional year-on-year earnings expansion, supported by healthy execution and sustained margin strength, reflecting continued momentum across its business segments.
I G Petrochemicals Q1 FY27 Results
CMP: ₹514 | M.Cap: ₹1,587 Cr | P/E: 19.4
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 618 | 524 | 470 | ▲ 31% | ▲ 18.0% |
| EBITDA (₹ Cr) | 112 | 66.6 | -0.69 | ▲ 16,358% | ▲ 68.2% |
| Net Profit (₹ Cr) | 66.4 | 28.1 | -13.0 | ▲ 611% | ▲ 136.3% |
| EPS (₹) | 21.58 | 9.12 | -4.22 | ▲ 611% | ▲ 136.6% |
Verdict
I G Petrochemicals delivered a strong Q1 FY27 performance with healthy revenue growth and a sharp turnaround in profitability. Sales increased 31% YoY and 18.0% QoQ, while EBITDA surged to ₹112 crore from a loss in the year-ago quarter, reflecting a significant improvement in operating efficiency. Net profit more than doubled sequentially and turned positive on a YoY basis, with EPS also showing a remarkable recovery. Overall, the quarter highlights improving business fundamentals and a strong operational rebound.
ASM Technologies Q1 FY27 Results
CMP: ₹4,946 | M.Cap: ₹7,215 Cr | P/E: 98.8
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 199 | 135 | 123 | ▲ 62% | ▲ 47% |
| EBITDA (₹ Cr) | 46.0 | 25.0 | 25.7 | ▲ 79% | ▲ 84% |
| Net Profit (₹ Cr) | 26.8 | 16.8 | 15.6 | ▲ 72% | ▲ 60% |
| EPS (₹) | 18.39 | 11.49 | 11.95 | ▲ 54% | ▲ 60% |
Verdict
ASM Technologies reported a strong Q1 FY27 performance, delivering robust growth across revenue, EBITDA, net profit, and EPS on both a YoY and QoQ basis. The sharp improvement in operating profitability highlights healthy execution and sustained business momentum. However, with the stock trading at a premium valuation of P/E 98.8, future earnings will need to remain strong to justify current market expectations.
Shilpa Medicare – Q1 FY27 Results Snapshot
CMP: ₹722 | M.Cap: ₹14,034 Cr | P/E: 49.4
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 466 | 437 | 321 | ▲ 45% | ▲ 7% |
| EBITDA (₹ Cr) | 136 | 120 | 90.9 | ▲ 50% | ▲ 13% |
| Net Profit (₹ Cr) | 101 | 108 | 46.9 | ▲ 115% | ▼ 6% |
| EPS (₹) | 5.16 | 5.51 | 2.40 | ▲ 115% | ▼ 6% |
Verdict
Shilpa Medicare reported a strong Q1 FY27 performance, driven by 45% YoY revenue growth and a 115% surge in net profit. EBITDA also expanded by 50% YoY, indicating healthy operating leverage and improved profitability. Although net profit and EPS witnessed a marginal sequential decline, the company’s overall operational performance remained robust, reflecting sustained business momentum and healthy execution.
Berger Paints – Q1 FY27 Results
CMP: ₹545 | M.Cap: ₹63,570 Cr | P/E: 51.8
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,584 | 2,868 | 3,201 | ▲ 12% | ▲ 25% |
| EBIDT (₹ Cr) | 607 | 482 | 528 | ▲ 15% | ▲ 26% |
| Net Profit (₹ Cr) | 405 | 335 | 315 | ▲ 29% | ▲ 21% |
| EPS (₹) | 3.47 | 2.87 | 2.70 | ▲ 29% | ▲ 21% |
Verdict
Berger Paints reported a strong Q1 FY27 performance with healthy double-digit revenue growth and even stronger profitability. Operating leverage and margin expansion helped earnings outpace sales growth, highlighting improved operational efficiency amid robust demand. The results indicate sustained business momentum and reinforce the company’s strong positioning in the decorative paints segment.
RattanIndia Enterprises Q1 FY27 Results
CMP: ₹32.6 | M.Cap: ₹4,498 Cr
| Particulars | Jun 2026 | Mar 2026 | Jun 2025 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,870 | 1,697 | 2,313 | ▼ 19% | ▲ 10% |
| EBITDA (₹ Cr) | 40.1 | -102 | 609 | ▼ 93% | ▲ Improved (Turnaround) |
| Net Profit (₹ Cr) | 14.7 | -110 | 502 | ▼ 97% | ▲ Improved (Turnaround) |
| EPS (₹) | 0.11 | -0.80 | 3.64 | ▼ 97% | ▲ Improved |
Verdict
Despite a sequential turnaround from the March quarter, RattanIndia Enterprises’ profitability remained sharply lower on a year-on-year basis. Revenue declined 19% YoY, while EBITDA and net profit fell 93% and 97%, respectively, reflecting weak operating performance. Although the company returned to profitability compared to the previous quarter, the overall earnings quality remains subdued. The results indicate that a sustained recovery is still awaited.
